Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Percutaneous Closure of Postinfarction Ventricular Septal Defect, an early alternative to surgery.

Original title: Percutaneous Closure of Postinfarction Ventricular Septal Defect: In-Hospital Outcomes and Long-Term Follow-Up of UK Experience. Reference: Circulation. 2014 Jun 10;129(23):2395-402.

As a mechanical post AMI complication, interventricular communication carries a grim prognosis. Surgery has achieved reasonable outcomes but only for those patients who survive the acute phase of healing. Percutaneous closure is a viable early alternative. 

Between 1997 and 2012 percutaneous closure of postinfarction ventricular septal defect was attempted in 53 patients at 11 UK centers. 66% of MI were anterior and 34% inferior. 

Time from MI to closure procedure was 13 days (5-54 range) and devices were successfully implanted in 89% of the population.

Immediate complications in this high risk population included periprocedural death in 3.8% and emergency cardiac surgery in 7.5% of the population.

Right to left shunt was partially occluded in most of patients (62%), completely occluded in 23% and failed despite device implantation in 15%.

58% of treated patients survived to discharge and were followed up to 395 days. During this period. four additional patients died (7.5%).

Factors more strongly associated to postinfarction mortality included age (HR 1.04; p=0.039), female sex (HR=2.33; p=0.043), NYHA functional class IV (HR=4.42; p=0.002), cardiogenic shock (HR=3.75; p=0.003), need for inotropes (HR=4.18; p=0.005) and the absence of revascularization for presenting MI (HR=3.28; p=0.009).

Prior surgical closure and immediate post implantation shunt reduction were associated with better survival.

Conclusion

Percutaneous closure is a reasonable alternative to treat post infarction percutaneous ventricular septal defect. Although mortality was high, patients who survived to discharge had a good long term prognosis. 

Editorial Comment

This option should be considered especially for those patients that develop cardiogenic shock as a symptom of ventricular septal defect, since surgery at the acute phase is difficult due to the friable nature of septal tissue and waiting, in this context, is hardly a viable option.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...